Wayne Holman Ridgeback Capital Investments Medicine ADAP, Adaptimmune, CLLS, ALCLS, Cellectis, FGEN, Fibrogen, MGNX, Macrogenics, AGTC, applied genetic technologies, SGMO, Sangamo, Trillium, TRIL, IRWD, Ironwood, UTHR, United Therapeautics, BMRN, Biomarin, CELG, Celgene, CLDX, Celldex, CMRX, Chi
Portfolio 19
| Date | Name | Website | Total Raised | Location |
| 05.02.2021 | Reverie | reverielabs.com | $25M | United Sta... |
| - | Epizyme | epizyme.com | $496M | United Sta... |
| - | Alder Biop... | alderbio.com | $38M | - |
| - | FibroGen | fibrogen.com | - | United Sta... |
| - | Cellectis | cellectis.com | - | United Sta... |
| - | Gilead Sci... | gilead.com | $304M | United Sta... |
| - | Sangamo Th... | sangamo.com | - | United Sta... |
| - | United The... | unither.com | - | United Sta... |
| - | Intercept ... | interceptpharma.com | $30M | United Sta... |
| - | MacroGenic... | macrogenics.com | - | United Sta... |
Show more
Mentions in press and media 2
| Date | Title | Description |
| 29.11.2021 | Syncona : Quell Therapeutics Raises $156 million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform | - Series B co-led by Jeito Capital, Ridgeback Capital Investments, SV Health Investors and Fidelity Management & Research Company LLC, alongside founding investor Syncona and includes a broad syndicate of international life science focu... |
| 29.11.2021 | Quell Therapeutics Raises $156 million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform | - Series B co-led by Jeito Capital, Ridgeback Capital Investments, SV Health Investors and Fidelity Management & Research Company LLC, alongside founding investor Syncona and includes a broad syndicate of international life science focu... |